Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen's Imbruvica Leads CLL Market Expansion In Europe

Executive Summary

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

You may also be interested in...



Shifting EU Treatment Paradigms In CLL

The CLL market segment in the EU will now include a first-line combination therapy of AbbVie’s venetoclax and Roche’s obinutuzumab, which has recently been approved by the European Commission.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.

AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo

The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel